Madrigal Pharmaceuticals Stock Alpha and Beta Analysis
| MDGL Stock | USD 347.45 18.21 5.53% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Madrigal Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Madrigal Pharmaceuticals over a specified time horizon. Remember, high Madrigal Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Madrigal Pharmaceuticals' market risk premium analysis include:
Beta 0.39 | Alpha 0.54 | Risk 4.61 | Sharpe Ratio 0.13 | Expected Return 0.58 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Madrigal |
Madrigal Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Madrigal Pharmaceuticals market risk premium is the additional return an investor will receive from holding Madrigal Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Madrigal Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Madrigal Pharmaceuticals' performance over market.| α | 0.54 | β | 0.39 |
Madrigal Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Madrigal Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Madrigal Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Madrigal Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Madrigal Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Madrigal Pharmaceuticals shares will generate the highest return on investment. By understating and applying Madrigal Pharmaceuticals stock market price indicators, traders can identify Madrigal Pharmaceuticals position entry and exit signals to maximize returns.
Madrigal Pharmaceuticals Return and Market Media
The median price of Madrigal Pharmaceuticals for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 234.76 with a coefficient of variation of 18.66. The daily time series for the period is distributed with a sample standard deviation of 46.74, arithmetic mean of 250.51, and mean deviation of 37.62. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 6363 shares by William Sibold of Madrigal Pharmaceuticals at 243.83 subject to Rule 16b-3 | 09/09/2024 |
2 | Disposition of 15000 shares by Craves Fred B of Madrigal Pharmaceuticals subject to Rule 16b-3 | 09/13/2024 |
3 | Disposition of 18917 shares by Taub Rebecca of Madrigal Pharmaceuticals at 245.3356 subject to Rule 16b-3 | 09/20/2024 |
4 | Disposition of 000 shares by Craves Fred B of Madrigal Pharmaceuticals subject to Rule 16b-3 | 10/04/2024 |
5 | Baker Bros. Advisors LP Increases Stake in Kiniksa Pharmaceuticals | 10/09/2024 |
6 | Acquisition by Friedman Paul A of 26270 shares of Madrigal Pharmaceuticals at 9.45 subject to Rule 16b-3 | 10/22/2024 |
7 | Madrigal Stock Soars 23 percent as NASH Drug Rezdiffra Crushes Expectations | 11/04/2024 |
8 | Insider Selling Madrigal Pharmaceuticals, Inc. Director Sells 5,000 Shares of Stock | 11/06/2024 |
9 | Disposition of 5000 shares by Levy Richard S of Madrigal Pharmaceuticals at 7.36 subject to Rule 16b-3 | 11/07/2024 |
10 | Cryoport vs. Madrigal Pharmaceuticals Head to Head Survey | 11/12/2024 |
11 | John Paulsons Strategic Acquisition in Madrigal Pharmaceuticals | 11/15/2024 |
12 | Wall Street Analysts Believe Madrigal Could Rally 26.44 percent Heres is How to Trade | 11/18/2024 |
13 | Disposition of 688 shares by Carole Huntsman of Madrigal Pharmaceuticals at 316.92 subject to Rule 16b-3 | 11/21/2024 |
14 | Madrigal Just Flashed Golden Cross Signal Do You Buy | 11/22/2024 |
About Madrigal Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Madrigal or other stocks. Alpha measures the amount that position in Madrigal Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 0.008267 | 0.007348 | Price To Sales Ratio | 3.3K | 3.4K |
Madrigal Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Madrigal Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Madrigal Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Madrigal Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Madrigal Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Madrigal Pharmaceuticals' management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Madrigal Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Madrigal Pharmaceuticals Backtesting, Madrigal Pharmaceuticals Valuation, Madrigal Pharmaceuticals Correlation, Madrigal Pharmaceuticals Hype Analysis, Madrigal Pharmaceuticals Volatility, Madrigal Pharmaceuticals History and analyze Madrigal Pharmaceuticals Performance. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Madrigal Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.